Advance Market Commitments for Vaccines Working Paper and Spread Sheet - Working Paper 98
Publication Info
Publication Type
Download
Initiatives
Research Topics
CGD Experts
Articles
- Drugmakers Rediscover Vaccine Niche
- Keep Hope
- Plan to fund vaccines for third world
- Report on Child Deaths Finds Some Hope in Poorest Nations [NYT]
Rights and Permissions
We welcome the use of CGD work-just let us know in advance! For contact information see our Rights & Permissions page. CGD rights and permissions are managed under the terms of the Creative Commons license below.
08/31/2006
By Ernst R. Berndt, Rachel Glennerster, Michael R. Kremer, Jean Lee, Ruth Levine, Georg Weizsacker and Heidi Williams
The G8 is considering committing to purchase vaccines against diseases concentrated in low-income countries (if and when desirable vaccines are developed) as a way to spur research and development on vaccines for these diseases. Under such an "advance market commitment," one or more sponsors would commit to a minimum price to be paid per person immunized for an eligible product, up to a certain number of individuals immunized. For additional purchases, the price would eventually drop to close to marginal cost. If no suitable product were developed, no payments would be made. We estimate the offer size which would make revenues similar to the revenues realized from investments in typical existing commercial pharmaceutical products, as well as the degree to which various model contracts and assumptions would affect the cost-effectiveness of such a commitment.
We make adjustments for lower marketing costs under an advance market commitment and the risk that a developer may have to share the market with subsequent developers. We also show how this second risk could be reduced, and money saved, by introducing a superiority clause to a commitment. Under conservative assumptions, we document that a commitment comparable in value to sales earned by the average of a sample of recently launched commercial products (adjusted for lower marketing costs) would be a highly cost-effective way to address HIV/AIDS, malaria, and tuberculosis. Sensitivity analyses suggest most characteristics of a hypothetical vaccine would have little effect on the cost-effectiveness, but that the duration of protection conferred by a vaccine strongly affects potential cost-effectiveness. Readers can conduct their own sensitivity analyses employing a web-based spreadsheet tool; a link to the tool is available on page 21 of the paper.